Document is current
Any future updates will be listed below
-
Authors
Cao, Yuqin https://orcid.org/0000-0003-0127-7557
Huang, Binhao
Tang, Han
Dong, Dong
Shen, Tianzheng
Chen, Xiang
Feng, Xijia
Zhang, Jiahao
Shi, Liqiang
Li, Chengqiang
Jiao, Heng
Tan, Lijie
Zhang, Jie
Li, Hecheng https://orcid.org/0000-0001-8069-6033
Zhang, Yajie
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03792347 at ClinicalTrials.govnct04435197 at ClinicalTrials.govDocuments that mention this clinical trial
Online tools to predict individualised survival for primary oesophageal cancer patients with and without pathological complete response after neoadjuvant therapy followed by oesophagectomy: development and external validation of two independent nomograms
https://doi.org/10.1136/bmjgast-2023-001253
High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy
https://doi.org/10.1136/jitc-2023-007847
nct04513418 at ClinicalTrials.govDocuments that mention this clinical trial
Online tools to predict individualised survival for primary oesophageal cancer patients with and without pathological complete response after neoadjuvant therapy followed by oesophagectomy: development and external validation of two independent nomograms
https://doi.org/10.1136/bmjgast-2023-001253
Role of pretreatment absolute lymphocyte count in survival outcomes for esophageal cancer treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
https://doi.org/10.1200/jco.2023.41.4_suppl.338
High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy
https://doi.org/10.1136/jitc-2023-007847
nct03001596 at ClinicalTrials.govDocuments that mention this clinical trial
Online tools to predict individualised survival for primary oesophageal cancer patients with and without pathological complete response after neoadjuvant therapy followed by oesophagectomy: development and external validation of two independent nomograms
https://doi.org/10.1136/bmjgast-2023-001253
nct03001596 at ClinicalTrials.govDocuments that mention this clinical trial
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
https://doi.org/10.1136/jitc-2022-005830
Online tools to predict individualised survival for primary oesophageal cancer patients with and without pathological complete response after neoadjuvant therapy followed by oesophagectomy: development and external validation of two independent nomograms
https://doi.org/10.1136/bmjgast-2023-001253
nct03001596 at ClinicalTrials.govDocuments that mention this clinical trial
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
https://doi.org/10.1136/jitc-2022-005830
Online tools to predict individualised survival for primary oesophageal cancer patients with and without pathological complete response after neoadjuvant therapy followed by oesophagectomy: development and external validation of two independent nomograms
https://doi.org/10.1136/bmjgast-2023-001253
Documents that mention this clinical trial
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
https://doi.org/10.1136/jitc-2022-005830
Online tools to predict individualised survival for primary oesophageal cancer patients with and without pathological complete response after neoadjuvant therapy followed by oesophagectomy: development and external validation of two independent nomograms
https://doi.org/10.1136/bmjgast-2023-001253
-
Funding
Funding for this research was provided by:
Shanghai Municipal Health Commission (Clinical Research Project in Health Services 20224)
Shanghai Municipal Health Commission (Novel Interdisciplinary Research Project 2022JC023)
Program of Shanghai Academic Research Leader (20XD1402300)
National Natural Science Foundation of China (82072557)
Shanghai Jiao Tong University (Interdisciplinary Program YG2023ZD04)
Shanghai Municipal Education Commission (Gaofeng Clinical Medicine Grant 20172005)
National Key Research and Development Program of China (2021YFC2500900)
- License Information
